Skip to content

Quest Diagnostics DGX Debt Issuance Proceeds

Debt Issuance Proceeds at other companies

Myriad Genetics logo
Myriad GeneticsMYGN
$0-100%
Opko Health logo
Opko HealthOPK
$10.18M-7.7%
NeoGenomics logo
NeoGenomicsNEO
$0
Agilent Technologies logo
Agilent TechnologiesA
$0
QuidelOrtho Corporation logo
QuidelOrtho CorporationQDEL
$12.6M
Revvity logo
RevvityRVTY

Other financials

Income statement

See full
Revenue$3.0B+10.2%
Gross profit$1.0B+8.9%
Operating income$459.0M+4.8%
Net income$320.0M+13.5%
EPS (diluted)$2.84+15.0%

Balance sheet

See full
Cash & equivalents$626.0M+96.2%
Total debt$6.4B0.0%
Total equity$7.5B+4.0%
Total assets$16.9B+6.1%

Cash flow

See full
Operating cash flow$597.0M+9.7%
CapEx$138.0M+27.8%
Free cash flow$459.0M+5.3%

Valuation

See full
Market cap$26.04B+38.7%
Enterprise value$31.8B+28.0%
P/E24.5×+4.8×
P/S2.3×+0.5×

Profitability

See full
Gross margin33.1%+0.1pp
Operating margin14.1%+0.1pp
Net margin9.2%+0.2pp
FCF margin11.7%0.0pp

Returns & leverage

See full
Return on equity14.4%+0.7pp
Debt / equity0.8×0.0×
Current ratio1.6×+0.5×

Where this comes from

Reported directly by Quest Diagnostics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfDebt.

The official record: Quest Diagnostics’s 10-Q, filed July 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about Quest Diagnostics's debt issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Quest Diagnostics's debt issuance proceeds?
Quest Diagnostics (DGX) reported debt issuance proceeds of $494M in Q2 2026.
How has Quest Diagnostics's debt issuance proceeds changed year-over-year?
Quest Diagnostics's debt issuance proceeds increased by 167.0% year-over-year, from $185M to $494M.
What does debt issuance proceeds mean?
Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.